

Publicaties 2010

Adank MA, Segers H, van Mil SE, van Helsdingen YM, Ameziane N, van den Ouweland AM, Wagner A, Meijers-Heijboer H, Kool M, de Kraker J, Waisfisz Q, van den Heuvel-Eibrink MM. Fanconi anemia gene mutations are not involved in sporadic Wilms tumor. **Pediatr Blood Cancer** 2010;55:742-744.

Aricò M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, Manabe A, Saha A, Baruchel A, Vettenranta K, Horibe K, Benoit Y, Pieters R, Escherich G, Silverman LB, Pui CH, Valsecchi MG. Clinical Outcome of Children With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005. **J Clin Oncol** 2010;28:4755-4761.

Bachas C, Schuurhuis GJ, Hollink IHIM, Kwidama ZL, Goemans BF, Zwaan CM, van den Heuvel-Eibrink MM, de Bont ESJM, Reinhardt D, Creutzig U, de Haas V, Assaraf YG, Kaspers GJL, Cloos J. High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. **Blood** 2010;116:2752-2758.

Balgobind BV, Lugthart S, Hollink IH, Arentsen-Peters STJCM, van Wering E, de Graaf SSN, Reinhardt D, Creutzig U, Kaspers GJL, de Bont ESJM, Sary J, Trka J, Zimmermann M, Beverloo HB, Pieters R, Delwel R, Zwaan CM, van den Heuvel-Eibrink MM. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukaemia. **Leukemia** 2010;24:942-949.

Balgobind BV, Hollink IHIM, Reinhardt D, van Wering E, de Graaf SSN, Baruchel A, Sary J, Beverloo HB, de Greef GE, Pieters R, Zwaan CM, van den Heuvel-Eibrink MM. Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique. **Eur J Cancer** 2101;46:1892-1899.

Balgobind BV, Zwaan CM, Reinhardt D, Arentsen-Peters TJCM, Hollink IHIM, de Haas V, Kaspers GJL, de Bont ESJM, Baruchel A, Sary J, Meyer C, Marschalek R, Creutzig U, den Boer ML, Pieters R, van den Heuvel-Eibrink MM. High *BRE* expression in pediatric *MLL*-rearranged AML is associated with favorable outcome. **Leukemia** 2010;24:2048-2055.

Batz C, Hasle H, Bergsträsser E, van den Heuvel-Eibrink MM, Zecca M, Niemeyer CM, Flotho C; European Working Group of Myelodysplastic Syndromes in Childhood (EWOG-MDS). Does SPRED1 contribute to leukemogenesis in juvenile myelomonocytic leukaemia (JMML)? **Blood** 2010;115:2557-2558.

Bekkering WP, Vliet Vlieland TP, Koopman HM, Schaap GR, Schreuder HW, Beishuizen A, Tissing WJ, Hoogerbrugge PM, Anninga JK, Taminiou AH. Quality of life in young patients after bone tumor surgery around the knee joint and comparison with healthy controls. **Pediatr Blood Cancer** 2010;54:738-745.

Boot AM, de Ridder MAJ, van der Sluis IM, van Slobbe I, Krenning EP, de Muinck Keizer-Schrama. Peak bone mineral density, lean body mass and fractures. **Bone** 2010;46:336-341.

Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, Asnafi V, Baruchel A, Bassan R, Benoit Y, Biondi A, Cavé H, Dombret H, Fielding AK, Foà R, Gökbüget N, Goldstone AH, Goulden N, Henze G, Hoelzer D, Janka-Schaub GE, Macintyre EA, Pieters R, Rambaldi A, Ribera JM, Schmiegelow K, Spinelli O, Sary J, von Stackelberg A, Kneba M, Schrappe M, van Dongen JJ; European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL); International Berlin-Frankfurt-Münster Study Group (I-BFM-SG). Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. **Leukemia** 2010;24:521-535.

Buitenkamp TD, Mathot RAA, de Haas V, Pieters R, Zwaan CM. Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. **Haematologica** 2010;95:1106-1113.

Crossen MH, Aarsen FK, van den Akker SLJ, Danen R, Appel IM, Steyerberg EW, Catsman-Berrevoets CE. Paediatric arterial ischaemic stroke: functional outcome and risk factors. **Dev Med Child Neuro** 2010;52:394-399.

Coenen EA, Zwaan CM, Meyer C, Marschalek R, Pieters R, van der Veken LT, Beverloo HB, van den Heuvel-Eibrink MM. KIAA1524: A novel MLL translocation partner in acute myeloid leukemia. **Leuk Res** 2010;35:133-135.

Dalen van EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivatives for reducing cardiotoxicity in cancer patients. **Cochrane Database Syst Rev** 2010;May 12;5:CD005006.

Eden TO, Pieters R, Richards S; Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG). Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia – an individual patient data meta-analysis involving 5659 children. **Br J Hematol** 2010;149:722-733.

Ehlers S, Herbst C, Zimmermann M, Scharn N, Germeshausen M, von Neuhoff N, Zwaan CM, Reinhardt K, Hollink IH, Klusmann JH, Lehrnbecher T, Roettgers S, Stary J, Dworzak M, Welte K, Creutzig U. Granulocyte Colony-Stimulating Factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. **J Clin Oncol** 2010;28:2591-2597.

Faaij CMJM, Willemze AJ, Révész T, Balzoroza M, Tensen CP, Hoogeboom M, Vermeer MH, van Wering E, Zwaan CM, Kaspers GJL, Story C, van Halteren AGS, Vossen JM, Egeler RM, van Tol MJD, Annels NE. Chemokine/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: differential roles for CCR2, CCR5, CXCR4 and CXCR7. **Pediatr Blood Cancer** 2010;55:344-348.

Flotho C, Batz C, Hasle H, Bergsträsser E, van den Heuvel-Eibrink MM, Zecca M, Niemeyer CM, Zenker M. Mutational analysis of *SHOC2*, a novel gene for Noonan-like syndrome, in JMML. **Blood** 2010;115:913.

Goemans BF, Zwaan CM, Cloos J, de Lange D, Loonen AH, Reinhardt D, Hähnen K, Gibson BE, Creutzig U, Kaspers GJ. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657. **Leuk Res** 2010;34:1302-1307.

Göhring G, Michalova k, Beverloo HB, Betts D, Harbott J, Haas OA, Kerndrup G, Sainati L, Bergstraesser E, Hasle H, Stary J, Trebo M, van den Heuvel-Eibrink MM, Zecca M, van Wering ER, Fischer A, Noelke P, Strahm B, Locatelli F, Niemeyer CM, Schlegelberger B. Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. **Blood** 2010;116:3766-3769.

Gooskens SL, Oranje AP, van Adrichem LN, de Waard-van der Spek FB, den Hollander JC, van de Ven CP, van den Heuvel-Eibrink MM. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP). **Pediatr Blood Cancer** 2010;55:369-373.

Gooskens SLM, Oranje AP, van Adrichem LNA, de Waard-van der Spek FB, den Hollander JC, van der Ven CP, van den Heuvel-Eibrink MM. Dermatofibrosarcoma protuberans (DFSP) bij kinderen. **Oncollectie** 2010;3:8-15.

Gravendeel LA, Kloosterhof NK, Bralten LB, van Marion R, Dubbink HJ, Dinjens W, Bleeker FE, Hoogenraad CC, Michiels E, Kros JM, van den Bent M, Smitt PA, French PJ. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. **Hum Mutat** 2010;31:E1186-E1199.

Hagemans ML, Stigter RL, van Capelle CI, van der Beek NA, Winkel LP, van Vliet L, Hop WC, Reuser AJ, Beishuizen A, van der Ploeg AT. PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe disease. **J Inherit Metab Dis** 2010;33:133-139.

Hartman A, van Schaik RHN, van der Heiden IP, Broekhuis MJC, Meier M, den Boer ML, Pieters R. Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. **Leuk Res** 2010;34:154-159.

Hempel G, Relling MV, de Rossi G, Sary J, De Lorenzo P, Valsecchi MG, Barisone E, Boos J, Pieters R. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the Interfant 99 protocol. **Pediatr Blood Cancer** 2010;54:355-360.

Heuvel-Eibrink van den MM, Dohle GR, de Muinck Keizer-Schrama, Laven JSE, Neggers SJ. Late effecten van kankerbehandeling bij kinderen. Deel 3: endocriene effecten. **Oncollectie** 2010;2:2-7.

Hollink IHIM, van den Heuvel-Eibrink MM, Zimmermann M, Balgobind M, Arentsen-Peters STCJM, Alders M, Willasch A, Kaspers GJL, Trka J, Baruchel A, Creutzig U, Pieters R, Reinhardt D, Zwaan CM. No prognostic impact of the *WT1* gene single nucleotide polymorphism rs16754 in pediatric acute myeloid leukemia. **J Clin Oncol** 2010;28:523-526.

Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, Whitlock JA. Toxicity assessment of molecular targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukaemia (ALL): review from an international consensus conference. **Pediatr Blood Cancer** 2010;54:872-878.

Jonge HJM, Valk PJM, Veeger NJGM, ter Elst A, den Boer ML, Cloos J, de Haas V, van den Heuvel-Eibrink MM, Kaspers GJL, Zwaan CM, Kamps WA, Löwenberg B, de Bont ESJM. High *VEGFC* expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. **Blood** 2010;116:1747-1754.

Jung R, Jacobs U, Krumbholz M, Langer T, Keller T, De Lorenzo P, Valsecchi MG, van der Velden VH, Moericke A, Stanulla M, Teigler-Schlegel A, Panzer-Gruemayer ER, van Dongen JJ, Schrappe M, den Boer ML, Pieters R, Rascher W, Metzler M. Bimodal distribution of genomic MLL breakpoints in infant acute lymphoblastic leukaemia treatment. **Leukemia** 2010;24:903-907.

Kamps WA, van der Pal-de Bruin KM, Veerman AJP, Fiocco M, Bierings M, Pieters R. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. **Leukemia** 2010;24:309-319.

Keersmaecker de K, Real PJ, Gatta GD, Palomero T, Sulis ML, Tosello V, Van Vlierberghe P, Barnes K, Castillo M, Sole X, Hadler M, Lenz J, Aplan PD, Kelliher M, Kee BL, Pandolfi PP, Kappes D, Gounari F, Petrie H, Van der Meulen J, Speleman F, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Soulier J, Avran D, Cavé H, Dastugue N, Raimondi S, Meijerink JP, Cordon-Cardo C, Califano A, Ferrando AA. The *TLX1* oncogene drives aneuploidy in T cell transformation. **Nat Med** 2010;16:1321-1327.

Kleppe M, Lahortiga I, El Chaar T, De Keersmaecker K, Mentens N, Graux C, Van Roosbroeck K, Ferrando AA, Langerak AW, Meijerink JP, Sigaux F, Haferlach T, Wlodarska I, Vandenberghe P, Soulier J, Cools J. Deletion of the protein tyrosine phosphatase gene *PTPN2* in T-cell acute lymphoblastic leukemia. **Nat Genet** 2010;42:530-535.

Landlinger C, Preuner S, Bašková. Van Grotel M, Hartwig NG, Dworzak M, Mann G, Attarbaschi A, Kager L, Peters C, Matthes-Martin S, Lawitschka A, van den Heuvel-Eibrink MM. Diagnosis of invasive fungal infections by a real-time panfungal PCR assay in immunocompromised pediatric patients. **Leukemia** 2010;24:2032-2038.

Lie Fong S, van den Heuvel-Eibrink MM, Eijkemans MJ, Schipper I, Hukkelhoven CW, Laven JS. Pregnancy outcome in female childhood cancer survivors. **Hum Reprod** 2010;25:1206-1210.

Linden van den MH, Seslija L, Schneider P, Pieters R, Stam RW. Establishing direct targets of MLL-AF4 fusion proteins in t(4;11)-positive acute lymphoblastic leukemia in infants. **Daniel den Hoed Cancer News** 2010;2:25-26.

Lijster de MS, Bergevoet RM, van Dalen EC, Michiels EM, Caron HN, Kremer LC, Aronson DC. Minimally invasive surgery versus open surgery for the treatment of solid abdominal and thoracic neoplasms in children. **Cochrane Database Syst Rev** 2010;Mar 17;3:CD008403.

Mann G, Attarbaschi A, Schrappe M, De Lorenzo P, Peters C, Hann I, De Rossi G, Felice M, Lausen B, LeBlanc T, Szczepanski T, Ferster A, Janka-Schaub G, Rubnitz J, Silverman LB, Stary J, Campbell M, Li CK, Suppiah R, Biondi A, Vora A, Valsecchi MG, Pieters R, on behalf of the Interfant-99 Study Group. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with *mixed-lineage-leukemia (MLL)*-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. **Blood** 2010;116:2644-2650.

Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Sakamoto KM, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlegel PG, Heinzmann A, Schneider M, Starý J, van den Heuvel-Eibrink MM, Hasle H, Locatelli F, Sakai D, Archambeault S, Chen L, Russell RC, Sybingco SS, Ohh M, Braun BS, Flotho C, Loh ML. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. **Nat Genet** 2010;42:794-800.

Pieters R, Carroll WL. Biology and treatment of acute lymphoblastic leukemia. **Hematol Oncol Clin N Am** 2010;24:1-18.

Pieters R. Childhood leukaemia: towards improved tailored therapy. **Lancet Oncol** 2010;11:403-404.

Pieters R. Stand van zaken. Behandeling van acute lymfatische leukemie bij kinderen en adolescenten. Zijn we er bijna? **Ned Tijdschr Geneesk** 2010;154:1644-1649.

Pieters R. Acute lymfatische leukemie bij kinderen en adolescenten. **Ned Tijdschr Hematol** 2010;7:177-186.

Raadt de B, Rijkschroeff J, van den Heuvel-Eibrink MM. Zorg op maat. Kinderpalliatieve zorg vanuit ouderbegeleidend perspectief. **Maatwerk** 2010;11:1:9-11.

Raadt de B. Veerkracht en moederschap. Beeld versus gedrag van moeder met stervend kind. **Maatwerk** 2010;11:1:7-8.

Raadt de B, Wijers E, Beishuizen A. 'Coping' bij hoge en langdurige stress. Ouders en een ernstig ziek kind. **Tijdschr Kinderverpleegk** 2010;16:22-25.

Schotte D, Lange-Turenhout EAM, Stumpel DJPM, Stam RW, Buijs-Gladdines JGCAM, Meijerink JPP, Pieters R, den Boer ML. Expression of miR-196b is not exclusively *MLL*-driven but is especially linked to activation of *HOXA* genes in pediatric acute lymphoblastic leukemia. **Haematologica** 2010;95:1675-1682.

Schrappe M, Nachman J, Hunger S, Schmiegelow K, Conter V, Masera G, Pieters R, Pui CH. Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985–2000). **Leukemia** 2010;24:253-254.

Smetzers SE, Zwaan CM, Sonneveld MC, Brakenhoff RH, Smiers FJ, Best JD, Joenje H, Bierings MB. Fanconi-anemie: uit de kinderschoenen. **Ned Tijdschr Hematol** 2010;7:230-240.

Stam RW, den Boer ML, Schneider P, de Boer J, Hagelstein J, Valsecchi MG, de Lorenzo P, Sallan SE, Brady HJM, Armstrong SA, Pieters R. Association of high-level *MCL-1* expression with in vitro and in vivo prednisone resistance in *MLL*-rearranged infant acute lymphoblastic leukaemia. **Blood** 2010;115:1018-1025.

Stam RW, Schneider P, Hagelstein JA, van der Linden MH, Stumpel DJ, de Menezes RX, de Lorenzo P, Valsecchi MG, Pieters R. Gene expression profiling-based dissection of MLL translocation and MLL germline acute lymphoblastic leukemia in infants. **Blood** 2010;115:2835-2844.

Stumpel DJPM, Schneider P, van Roon EHJ, Boer JM, de Lorenzo P, Valsecchi MG, de Menezes RX, Pieters R, Stam RW. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. **Blood** 2010;114:5490-5498.

Vlierberghe van P, Palomero T, Khiabanian H, Van der Meulen J, Castillo M, Van Roy N, De Moerloose B, Philippé J, González-García S, Toribio ML, Taghon T, Zuurbier L, Cauwelier B, Harrison CJ, Schwab C, Pisecker M, Strehl S, Langerak AW, Gecz J, Sonneveld E, Pieters R, Paietta E, Rowe JM, Wiernik PH, Benoit Y, Soulier J, Poppe B, Yao X, Cordon-Cardo C, Meijerink J, Rabadan R, Speleman F, Ferrando A. PHF6 mutations in T-cell acute lymphoblastic leukaemia. **Nat Genet** 2010;42:338-342

Vries de ACJH, Zwaan CM, van den Heuvel-Eibrink MM. Molecular basis of juvenile myelomonocytic leukemia. **Haematologica** 2010;95:179-182.

Waas van M, Neggers SJ, van der Lelij AJ, Pieters R, van den Heuvel-Eibrink MM. The metabolic syndrome in adult survivors of childhood cancer, a review. **J Pediatr Hematol Oncol** 2010;32:171-179.

Waas van M, Neggers SJ, Pieters R, van den Heuvel-Eibrink MM. Components of the metabolic syndrome in 500 adult long-term survivors of childhood cancer. **Ann Oncol** 2010;21:1121-1126.

Winkel te ML, Lequin MH, de Bruyn JR, van de Ven CP, de Krijger RR, Pieters R, van den heuvel-Eibrink MM. Self-limiting sternal tumors of childhood (SELSTOC). **Pediatr Blood Cancer** 2010;55:81-84.

Winkel te ML, van Beek RD, de Muinck Keizer-Schrama SM, Uitterlinden AG, Hop WC, Pieters R, van den Heuvel-Eibrink MM. Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukaemia. **Haematologica** 2010;95:752-759.

Winkel te ML, van der Sluis IM, Lequin MH, Pieters R, van den Heuvel-Eibrink MM. Letter to the editor in response to "Prospective bone ultrasound patterns during childhood acute lymphoblastic leukemia" by Mussa et al. **Bone** 2010;47:835-836.

Winkel te ML, Pieters R, van den Heuvel-Eibrink MM. Future perspectives on minimizing bone density reduction in pediatric acute lymphoblastic leukemia. **Personalized Medicine** 2010;7:469-471.

Zuurbier L, Homminga I, Calvert V, te Winkel ML, Buijs-Gladdines JGCAM, Kooi C, Smits WK, Sonneveld E, Veerman AJP, Kamps WA, Horstmann M, Petricoin III EF, Pieters R, Meijerink JPP. *NOTCH1* and/or *FBXW7* mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. **Leukemia** 2010;24:2014-2022.

Zwaan CM, Reinhardt D, Hitzler J, Vyas P. Acute leukemias in children with down syndrome. **Hematol Oncol Clin N Am** 2010;24:19-34.

Zwaan CM, Kearns P, Caron H, Verschuur A, Riccardi R, Boos J, Doz F, Geoerger B, Morland B, Vassal G, On behalf of the 'innovative therapies for children with cancer' European consortium. The role of the 'innovative therapies for children with cancer' (ITCC) European consortium. **Cancer Treat Rev** 2010;36:328-334.

Zwaan CM, Reinhardt D, Zimmermann M, Hasle H, Stary J, Stark B, Dworzak M, Creutzig U, Kaspers GJL, on behalf of the International BFM Study Group on Paediatric AML. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. **Br J Haematol** 2101;148:768-776.